Perceptive Advisors Portfolio holdings
Perceptive Advisors is a life sciences investment firm whose flagship Perceptive Life Sciences Fund puts most of its money into publicly traded small and mid-sized companies. Joseph Edelman, a former senior analyst at Paramount Capital's Aries Fund, a biotechnology hedge fund, founded the firm in 1999. It launched its first credit fund in 2013, and in 2019 teamed up with the biotech startup accelerator Xontogeny to launch its first venture capital fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freenome
FRNM
|
+$173M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$59.3M |
| 3 |
Waters
WAT
|
+$54.1M |
| 4 |
Opus Genetics
IRD
|
+$37.4M |
| 5 |
Abbott
ABT
|
+$36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuvalent
NUVL
|
+$195M |
| 2 |
Apogee Therapeutics
APGE
|
+$174M |
| 3 |
Spyre Therapeutics
SYRE
|
+$100M |
| 4 |
Roivant Sciences
ROIV
|
+$57.1M |
| 5 |
Biogen
BIIB
|
+$52.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.62% |
| 2 | Miscellaneous | 7.23% |
| 3 | Financials | 0.14% |
Similar funds
Perceptive Advisors's Q3 2026 Portfolio in Review
As of Q3 2026, Perceptive Advisors held 134 positions worth $5.74B, down 14% from $6.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors withdrew a net $726M in Q3 2026, closing 26 positions and reducing 43 holdings. Its most notable exit was Nuvalent, an estimated $195M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Freenome worth $199M.
- Perceptive Advisors's largest Q3 2026 buy was Freenome: 12,606,053 shares worth $199M.
- Perceptive Advisors added most to Amylyx Pharmaceuticals in Q3 2026, an estimated $59.3M increase.
- Perceptive Advisors's biggest Q3 2026 reduction was Spyre Therapeutics, cutting an estimated $100M.
- Perceptive Advisors fully exited Nuvalent in Q3 2026, selling an estimated $195M.
- Perceptive Advisors's ten largest holdings make up 50% of its $5.74B portfolio in Q3 2026.
- Perceptive Advisors opened 25 new positions and closed 26 in Q3 2026.
- Perceptive Advisors's portfolio value fell 14% quarter-over-quarter to $5.74B.
Based on Perceptive Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.